Gene-editing treatments for sickle cell disease may be out of reach for many
December 08, 2023
December 08, 2023
ANN ARBOR, Michigan, Dec. 8 -- The University of Michigan issued the following news release:
EXPERT Q&A
Federal approval of a breakthrough gene-editing technology that treats the pain and debilitating effects of sickle cell disease is cause for celebration among a community with few options for relief.
The Food and Drug Administration's approval of two gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease means more patients--100,000-p . . .
EXPERT Q&A
Federal approval of a breakthrough gene-editing technology that treats the pain and debilitating effects of sickle cell disease is cause for celebration among a community with few options for relief.
The Food and Drug Administration's approval of two gene therapies, Casgevy and Lyfgenia, to treat sickle cell disease means more patients--100,000-p . . .